Clinical Trial Commences for JR-446 in Treating MPS IIIB Condition#Japan#Chūō_City#JR-446#MPS_IIIB#J-Brain_Cargo
Clinical Trial Commences for JR-446 in Treating MPS IIIB Condition
MediPal Holdings and JCR Pharma announce the start of the global clinical trial for JR-446, targeting the rare condition MPS IIIB.
third-news.com
September 11, 2026 at 1:41 AM
Clinical Trial Commences for JR-446 in Treating MPS IIIB Condition#Japan#Chūō_City#JR-446#MPS_IIIB#J-Brain_Cargo